NCT01375361

Nebulized Albuterol for Congestive Heart Failure Exacerbation

• Status: Withdrawn
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.

Detailed description

The objective is to carry out a randomized blinded placebo-controlled trial of inhaled Albuterol as an early therapy for patients with decompensated Congestive Heart Failure. Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.

Conditions

• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Albuterol	2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
DRUG	Normal Saline	2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.

Timeline

• Start date: 2009-04-01
• Primary completion: 2010-07-01
• First posted: 2011-06-17
• Last updated: 2013-10-10

Locations

1 site across 1 country: United States